Page last updated: 2024-12-07

n-hydroxysuccinimide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-Hydroxysuccinimide (NHS) is a heterocyclic compound with the formula C4H5NO3. It is a white solid that is soluble in water, ethanol, and diethyl ether. NHS is used as an activating agent in organic synthesis, particularly in the formation of amide bonds. In peptide synthesis, NHS is used to activate carboxylic acids, making them more reactive towards amines. This allows for the coupling of amino acids to form peptides. NHS is also used in the synthesis of other compounds, such as esters, carbonates, and carbamates. NHS can be synthesized by the reaction of succinic anhydride with hydroxylamine. Its importance stems from its versatility in organic synthesis, particularly in the field of peptide chemistry. It is studied extensively due to its ability to facilitate efficient amide bond formation, which is crucial in the production of therapeutic peptides and proteins.'

N-hydroxysuccinimide: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID80170
CHEMBL ID403753
SCHEMBL ID1123
MeSH IDM0041619

Synonyms (69)

Synonym
AC-15786
unii-mje3791m4t
mje3791m4t ,
2,5-pyrrolidinedione, 1-hydroxy-
NCIOPEN2_000470
1-hydroxysuccinimide
1-hydroxy-2,5-pyrrolidinedione
2, 1-hydroxy-
hydroxysuccinimide
nsc74335
6066-82-6
n-hydroxysuccinimide
nsc-74335
succinimide, n-hydroxy-
NHS ,
inchi=1/c4h5no3/c6-3-1-2-4(7)5(3)8/h8h,1-2h
n-hydroxysuccinimide, 98%
einecs 228-001-3
nsc 74335
ccris 2604
AC-10509
hosu
B0249
CHEMBL403753
n-hydroxyl succinimide
H0623
1-hydroxypyrrolidine-2,5-dione
AKOS000121489
A8451
1-hydroxypyrrolidine-2,5-dione;n-hydroxysuccinimide (hosu)
n-hydroxy-succinimide
n-hydroxysuccinimid
n-hydroxysuccinimde
BP-13159
FT-0635964
PS-4557
AB00437
n-hydroxysuccinimide [inci]
n-hydroxysuccinimide [mi]
hydroxysuccinimide, n-
n-hydroxy-2,5-dioxopyrrolidine
n-hydroxypyrrolidine-2,5-dione
AM83849
SCHEMBL1123
1-hydroxy-pyrrolidine-2,5-dione
n-hy dr oxy succinimide
hosu.
hydroxy-pyrrolidine-2,5-dione
n-hydroxysuccin imide
n-hyroxysuccinimide
n-hydroxysucinimide
n-hydroxy succinimide
n-hydroxysuccinic acid imide
DTXSID7064102
Q-201468
n-hydroxylsuccinimide
STR01867
sigma 130672
mfcd00005516
CS-W008598
F0001-1588
n-hydroxysuccinimide (hosu)
n-hydroxysuccinimide, purum, >=97.0% (t)
Z56933833
SY001334
Q408833
STL183832
EN300-17439
n-hydroxysuccinimide (nhs)

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"Studies are described that sought the basis for a discrepancy in values for a key kinetic parameter of methotrexate transport (influx Vmax) in L1210 cells derived alternately from biochemical or pharmacokinetic measurements."( Enhancement of folate analogue transport inward in L1210 cells during methotrexate therapy of leukemic mice: evidence of the nature of the effect, possible host mediation, and pharmacokinetic significance.
Barrueco, JR; Poser, RE; Sirotnak, FM, 1987
)
0.27

Dosage Studied

ExcerptRelevanceReference
"Tethering of growth factors to biomaterial substrates via a polyethylene glycol (PEG) spacer has been established as a means of controlling dosage and conformation of the protein at the material surface, while retaining biological activity."( Characterization of EGF coupling to aminated silicone rubber surfaces.
Klenkler, BJ; Sheardown, H, 2006
)
0.33
" Using EIS, three OrXs (Or10a, Or22a and Or35a) showed a shift in their dose-response curves when Orco was co-integrated, reflecting an increase in ligand sensitivity and a decrease in limit of detection (LOD)."( Synergistic improvement in the performance of insect odorant receptor based biosensors in the presence of Orco.
Carraher, C; Hamiaux, C; Khadka, R; Kralicek, A; Travas-Sejdic, J, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (2 Product(s))

Product Categories

Product CategoryProducts
Beauty & Personal Care2

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Eczema Honey Multi Peptide Eye Cream -- 0.5 ozEczema HoneyBeauty & Personal Carecitric acid, chlorhexidine digluconate, benzoic acid, escin, cetyl alcohol, cetyl palmitate, chrysin, citric acid, tocopherol, hydroxyapatite, ethylhexylglycerin, tocopherol, glyceryl stearates, glycerin, n-hydroxysuccinimide, oat, phenoxyethanol, sodium citrate2024-11-29 10:47:42
Timeless Skin Care Dark Circle Eye Cream with Hyaluronic Acid + Haloxyl + Eyeliss -- 0.5 ozTimeless Skin CareBeauty & Personal Carebutylene glycol, benzylalcohol, carbomer, chrysin, glycerin, hesperidin methyl chalcone, n-hydroxysuccinimide, dipeptide-22024-11-29 10:47:42

Protein Targets (2)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bromodomain-containing protein 4Homo sapiens (human)DC5050.00000.00510.05330.1000AID1870319
Protein cereblonHomo sapiens (human)DC5050.00000.00800.48352.1000AID1870319
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
regulation of transcription by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
chromatin organizationBromodomain-containing protein 4Homo sapiens (human)
DNA damage responseBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionBromodomain-containing protein 4Homo sapiens (human)
positive regulation of DNA-templated transcriptionBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
regulation of inflammatory responseBromodomain-containing protein 4Homo sapiens (human)
positive regulation of T-helper 17 cell lineage commitmentBromodomain-containing protein 4Homo sapiens (human)
protein ubiquitinationProtein cereblonHomo sapiens (human)
positive regulation of Wnt signaling pathwayProtein cereblonHomo sapiens (human)
negative regulation of protein-containing complex assemblyProtein cereblonHomo sapiens (human)
positive regulation of protein-containing complex assemblyProtein cereblonHomo sapiens (human)
negative regulation of monoatomic ion transmembrane transportProtein cereblonHomo sapiens (human)
locomotory exploration behaviorProtein cereblonHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProtein cereblonHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingBromodomain-containing protein 4Homo sapiens (human)
p53 bindingBromodomain-containing protein 4Homo sapiens (human)
chromatin bindingBromodomain-containing protein 4Homo sapiens (human)
transcription coregulator activityBromodomain-containing protein 4Homo sapiens (human)
transcription coactivator activityBromodomain-containing protein 4Homo sapiens (human)
protein bindingBromodomain-containing protein 4Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityBromodomain-containing protein 4Homo sapiens (human)
enzyme bindingBromodomain-containing protein 4Homo sapiens (human)
lysine-acetylated histone bindingBromodomain-containing protein 4Homo sapiens (human)
RNA polymerase II C-terminal domain bindingBromodomain-containing protein 4Homo sapiens (human)
P-TEFb complex bindingBromodomain-containing protein 4Homo sapiens (human)
histone reader activityBromodomain-containing protein 4Homo sapiens (human)
protein bindingProtein cereblonHomo sapiens (human)
transmembrane transporter bindingProtein cereblonHomo sapiens (human)
metal ion bindingProtein cereblonHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
condensed nuclear chromosomeBromodomain-containing protein 4Homo sapiens (human)
nucleusBromodomain-containing protein 4Homo sapiens (human)
nucleoplasmBromodomain-containing protein 4Homo sapiens (human)
nucleusProtein cereblonHomo sapiens (human)
cytoplasmProtein cereblonHomo sapiens (human)
cytosolProtein cereblonHomo sapiens (human)
membraneProtein cereblonHomo sapiens (human)
perinuclear region of cytoplasmProtein cereblonHomo sapiens (human)
Cul4A-RING E3 ubiquitin ligase complexProtein cereblonHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1870320PROTAC activity at CBRN/BRD4 in human HEK293T cells assessed as degradation of BRD4 at 20 mM incubated for 24 hrs by HiBiT assay relative to control2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation.
AID1870321Cytotoxicity against human HEK293 cells assessed as inhibition of cell viability incubated for 30 mins by cell titer-glo assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation.
AID329100Activation of mouse TRPA1 expressed in CHO cells at 100 uM by calcium imaging FLIPR assay2007Nature, Feb-01, Volume: 445, Issue:7127
Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines.
AID1870317Cytotoxicity against human HEK293 cells assessed as inhibition of cell viability incubated for 30 mins in presence of CRBN-tracer by nanoBRET assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation.
AID1870318Cytotoxicity against permeabilized HEK293 cells assessed as inhibition of cell viability incubated for 30 mins in presence of CRBN-tracer by nanoBRET assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation.
AID1870322Cytotoxicity against human HEK293 cells assessed as inhibition of cell viability at 20 mM incubated for 30 mins by cell titer-glo assay relative to control2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation.
AID1870319PROTAC activity at CBRN/BRD4 in human HEK293T cells assessed as degradation of BRD4 incubated for 24 hrs by HiBiT assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (412)

TimeframeStudies, This Drug (%)All Drugs %
pre-199023 (5.58)18.7374
1990's37 (8.98)18.2507
2000's93 (22.57)29.6817
2010's218 (52.91)24.3611
2020's41 (9.95)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 56.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index56.35 (24.57)
Research Supply Index6.08 (2.92)
Research Growth Index5.04 (4.65)
Search Engine Demand Index95.01 (26.88)
Search Engine Supply Index2.04 (0.95)

This Compound (56.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (0.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other432 (99.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]